Ottobre 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) è stato approvato dalla Food and Drug Administration per pazienti adulti e pediatrici di età pari o superiore a 12 anni con tiroide localmente avanzata o metastatica differenziata.
Lenvatinib (Lenvima) New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was app..